COMBINATION THERAPY USING AN ANTI-EGFR AGENT(S) AND IGF-1R SPECIFIC INHIBITORS

摘要

The combination of an IGF-1R antagonist such as a humanized antibody and an anti-proliferative drug is described. In a preferred embodiment, the present invention describes the combination of an IGF-1R antibody and an anti-proliferative drug belonging to the EGFR-inhibitor class, which is preferably erlotinib. The combination according to the present invention is useful for the treatment of tumours, including IGF-1R and /or EGFR mediated or dependent tumours.